James Van Der Beek is sharing the subtle colorectal cancer symptom he ignored before his shocking diagnosis. “There wasn’t ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.